SCHEMBL13089969

SCHEMBL13089969

N#Cc1cccc(-c2cc(NC3CCN(S(=O)(=O)C4CC4)CC3)c3cnccc3c2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.43
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
CCR6 P51684 3/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
PRKCZ Q05513 5/20 0.40
PRKD2 Q9BZL6 4/20 0.40
GPR6 P46095 2/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CNR1 P21554 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
PIK3CA P42336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087843 0.92 ROCK2 (0.42) ROCK2CYP11B1CYP11B2CCR6IRAK4
SCHEMBL2424533 0.91 ROCK2 (0.43) ROCK2CCR6IRAK4PRKCZPRKD2
SCHEMBL13087712 0.90 ROCK2 (0.45) ROCK2CYP11B1CYP11B2CCR6PRKCZ
SCHEMBL13087664 0.90 CYP11B1 (0.42) ROCK2CYP11B1CYP11B2CCR6IRAK4
SCHEMBL13087490 0.90 CCR6 (0.46) ROCK2CYP11B1CYP11B2CCR6IRAK4
SCHEMBL13087792 0.90 PIK3CA (0.42) ROCK2CCR6IRAK4PRKCZPRKD2
SCHEMBL13087706 0.89 ROCK2 (0.42) ROCK2CCR6IRAK4PRKCZPRKD2
SCHEMBL13087153 0.89 CCR6 (0.51) ROCK2CCR6PRKCZPRKD2CCNA2
SCHEMBL13090008 0.89 CCR6 (0.51) ROCK2CYP11B1CYP11B2CCR6GPR6
SCHEMBL13087357 0.89 CNR1 (0.40) ROCK2CYP11B1CYP11B2CCR6IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 ROCK2 1065/4885CYP11B1 353/4885CYP11B2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.